NASDAQ: ARTV - Artiva Biotherapeutics, Inc.

Rentabilité sur six mois: -81.61%
Rendement en dividendes: 0.00%

Calendrier des promotions Artiva Biotherapeutics, Inc.


À propos de l'entreprise Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

plus de détails
It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

IPO date 2024-07-19
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.artivabio.com
Цена ао 3.64
Changement de prix par jour: 0% (2.35)
Changement de prix par semaine: +18.09% (1.99)
Changement de prix par mois: -59.97% (5.87)
Changement de prix sur 3 mois: -66.99% (7.12)
Changement de prix sur six mois: -81.61% (12.78)
Evolution des prix depuis le début de l'année: -77.79% (10.58)

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 1.26 10
Total: 3.75

Efficacité

Nom Signification Grade
ROA, % -26.35 0
ROE, % 17.09 5
Total: 1.83

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.5809 10
Total: 9.6

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 1574.6 10
Rentabilité Ebitda, % 60.31 8
Rentabilité EPS, % 189.36 10
Total: 9

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Fred Aslan M.D. President, CEO & Director 1975 (50 années)
Dr. Peter Flynn Ph.D. Co-Founder & Strategic Advisor 1974 (51 année)
Ms. Jennifer Kinsbruner Bush Esq., J.D. Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer 1975 (50 années)
Mr. Christopher P. Horan Chief Technical Operations Officer 1967 (58 années)
Ms. Neha Krishnamohan CFO & Executive VP of Corporate Development 1987 (38 années)
Dr. Thorsten Graef M.D., Ph.D. Chief Medical Officer 1976 (49 années)
Dr. Heather Raymon Ph.D. Senior Vice President of Research & Early Development 1964 (61 année)
Mr. Eugene Helsel Senior Vice President of Regulatory Affairs
Dr. K. C Lim Pharm.D. Senior Vice President of Clinical Operations

Adresse: United States, San Diego, 5505 Morehouse Drive - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.artivabio.com